FCFS

161.84

-0.36%↓

RPT.US

2.56

+3.64%↑

FCFS

161.84

-0.36%↓

RPT.US

2.56

+3.64%↑

FCFS

161.84

-0.36%↓

RPT.US

2.56

+3.64%↑

FCFS

161.84

-0.36%↓

RPT.US

2.56

+3.64%↑

FCFS

161.84

-0.36%↓

RPT.US

2.56

+3.64%↑

Search

Equasens

Gesloten

41.8 2.58

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

40.85

Max

42.3

Belangrijke statistieken

By Trading Economics

Inkomsten

-1.8M

17M

Verkoop

7.2M

116M

K/W

Sectorgemiddelde

15.69

Dividendrendement

3.29

Winstmarge

14.879

Werknemers

1,400

EBITDA

178M

116M

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

3.29%

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-44M

564M

Vorige openingsprijs

39.22

Vorige sluitingsprijs

41.8

Equasens Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

11 nov 2025, 23:59 UTC

Winsten

Singtel's 1st Half Net Profit Surges

11 nov 2025, 22:23 UTC

Acquisities, Fusies, Overnames

Mineral Resources Sells Stake in Lithium Mines to Posco For $765 Million

11 nov 2025, 22:21 UTC

Winsten

Aristocrat Boosts Dividend as Annual Profit Rises 12%

11 nov 2025, 23:52 UTC

Marktinformatie

Gold Rises Amid Fed Rate-Cut Prospects -- Market Talk

11 nov 2025, 23:44 UTC

Winsten

Singtel's 1H Net Profit Surges

11 nov 2025, 23:42 UTC

Marktinformatie

Nikkei May Trade Rangebound Amid Caution over U.S. Econ Strength -- Market Talk

11 nov 2025, 23:18 UTC

Winsten

Singtel: Expects FY Operating Company EBIT to Grow Between High Single Digits and Low Double Digits Vs. Earlier Guidance of High Single-Digit Growth >Z74.SG

11 nov 2025, 23:15 UTC

Winsten

Singtel: Interim Dividend of 8.2 Singapore Cents per Share, up 17% >Z74.SG

11 nov 2025, 23:14 UTC

Winsten

Singtel 1H Underlying Net Profit S$1.35B, Up 14% >Z74.SG

11 nov 2025, 23:12 UTC

Winsten

Singtel 1H Net Exceptional Gain of S$2.05B >Z74.SG

11 nov 2025, 23:11 UTC

Winsten

Singtel 1H Net S$3.40B Vs. Net S$1.23B >Z74.SG

11 nov 2025, 23:10 UTC

Winsten

Singtel 1H Rev S$6.91B Vs. S$6.99B >Z74.SG

11 nov 2025, 23:04 UTC

Marktinformatie

RBA Will Sharply Focus On Australian Jobs Report -- Market Talk

11 nov 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

11 nov 2025, 21:50 UTC

Marktinformatie
Winsten

Health Care Roundup: Market Talk

11 nov 2025, 21:46 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Private Equity Can Benefit From 'Deal-Friendly' Antitrust Policies -- Market Talk

11 nov 2025, 21:41 UTC

Winsten

Aristocrat: Continues to Actively Pursue Strategic M&A Opportunities

11 nov 2025, 21:40 UTC

Winsten

Aristocrat: Expects to Deliver Npata Growth Over FY 2026 on a Constant Currency Basis

11 nov 2025, 21:39 UTC

Winsten

Aristocrat: Interactive Delivered Revenue Growth Mainly Due to Inclusion of NeoGames

11 nov 2025, 21:39 UTC

Winsten

Aristocrat: Key Social Casino Franchises Continued to Outperform Market

11 nov 2025, 21:39 UTC

Winsten

Aristocrat: Gaming Unit Continued to Deliver Market Share Gains

11 nov 2025, 21:38 UTC

Winsten

Aristocrat: FY Normalized Npata Up 9% in Constant Currency

11 nov 2025, 21:38 UTC

Winsten

Aristocrat: Final Dividend 49 Australian Cents/Share

11 nov 2025, 21:37 UTC

Winsten

Aristocrat: FY Statutory Net Profit from Continuing Ops A$1.18 Bln, Up 2.9%

11 nov 2025, 21:36 UTC

Winsten

Aristocrat: FY Normalized Operating Revenue A$6.3 Bln, Up 11%

11 nov 2025, 21:35 UTC

Winsten

Aristocrat: FY Normalized Npata A$1.55 Bln, Up 12.2%

11 nov 2025, 21:35 UTC

Winsten

Alcon 3Q Adj EPS 79c >ALC

11 nov 2025, 21:35 UTC

Winsten

Alcon 3Q Rev $2.61B >ALC.EB

11 nov 2025, 21:35 UTC

Winsten

Alcon Backs 2025 EPS $3.05-EPS $3.15 >ALC.EB

11 nov 2025, 21:35 UTC

Winsten

Alcon 3Q EPS 48c >ALC.EB

Peer Vergelijking

Prijswijziging

Equasens Prognose

Beoordelingsconsensus

By TipRanks

0 ratings

0

Buy

0

Hold

0

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Equasens

Equasens Société anonyme provides healthcare IT solutions in Europe. The company develops electronic equipment, digital and robotic health, and equipment lease financing solutions. It also offers id., a pharmacy management software suite; id. PATIENT for the exchange of healthcare data; id. VENTE, which facilitates and secures prescription sales; id. COMMANDE, which manages orders and inventory; dispensing robots; Ségur id. services; FARMACLICK, a communication protocol; DIFARM, a modular solution for wholesalers-distributors; and PHARE, a retail management tool. In addition, the company offers patient medication adherence, patient loyalty, point-of-sale commercial performance, piloting pharmacy operations, pharmacy team training, securing pharmacy operations and health data, and digital communication solutions; and in-home nursing services and hospital-at-home, hospitals, and telemedicine solutions. Further, it provides id. DESK, an informative and interactive dashboard; id. UP!, a smartphone app; id. EASYQ, a queuing management solution; Miaterapia, a patient app; and MediStory for tracking patient records; ExpressVitale module; and MEDILINK, a health data hosting provider. Additionally, the company offers KAP&LINK2, a terminal with smart card and NFC reader; eS-KAP-Ad, a mobile device with a pre-loaded software; KAP-INSIDE, a mobile terminal; TI-KAP, which allows access to contact and contactless cards; AUTHENTIFICATEUR, a patented patient authentication system; KAP'TEUR by KAPELSE, a patented universal sensor; and NOVIAcare, which analyzes the behavior and activity of the elderly. It serves nursing homes, hospitals, in-house nursing care and hospital-at-home programs, regional health professional communities, multidisciplinary group practices, and individual healthcare professionals. The company was incorporated in 1996 and is headquartered in Villers-les-Nancy, France. Equasens Société anonyme is a subsidiary of Marque Verte Sante.
help-icon Live chat